Entasis Therapeutics Holdings's - ETTX market analysis on 23rd September 2020

Transaction Date	Recipient	Shares	Type	Price	Value
1st September 2020	Inc. Innoviva,	4,672,897	Open or private purchase	$2.68	$12,499,999.48
11th June 2020	Inc. Innoviva,	12,677,490	Open or private purchase	$2.50	$31,693,725.00
27th March 2020	Inc. Innoviva,	7,717,661	Open or private purchase	$2.87	$22,149,687.07
4th February 2020	Life Sciences Viii, L.P. Frazier	6,360,272	Conversion of derivative	$0.00
4th February 2020	Life Sciences Viii, L.P. Frazier	2,099,019	Conversion of derivative	$0.00
4th February 2020	Life Sciences Viii, L.P. Frazier	1,074,467	Conversion of derivative	$0.00
4th February 2020	Life Sciences Viii, L.P. Frazier	500,000	Open or private purchase	$17.00	$8,500,000.00
9th January 2020	Life Sciences Viii, L.P. Frazier	50,000	Open or private sale	$5.00	$250,010.00
18th January 2019	Life Sciences Viii, L.P. Frazier	372,439	Open or private purchase	$5.37	$1,999,997.43

Entasis Therapeutics Holdings

Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections.

Ticker: ETTX

Sector: Healthcare

Industry: Biotechnology

SEC Central Index Key (CIK): 1724344

Employees: 33

Exchange: NASDAQ

Auditor Opinion:

You must Login to see Language Changes

Disclosure Language changes

Analysis of subtle changes in disclosure language. Red is a sign of more constrained, less positive language changes etc. Green is more positive, less constrained etc.

You must Login to see analysis